
Three Aussie Stocks to Watch
Reports that a unit of Evergrande has negotiated a coupon payment with bondholders and a significant injection of liquidity from the Peoples Bank of China this morning has further eased fears over Chinese property developer Evergrande, prompting a recovery in the ASX200.
Share this:
Below are three Aussie stocks worth watching:
1. Orocobre (ORE)
Orocobre is a lithium producer whose share price has benefited in recent months from a lift in lithium’s price to multi-year highs due to the global move towards decarbonisation and tight supply. Yesterday the share price of Orocobre traded to a low of $8.19, almost 20% below its $10.08 high of last week as speculative money exited the space courtesy of the Evergrande scare and following a broker downgrade. Technically this week’s pullback is viewed as part of a corrective pullback. Providing technical support $8.20/10 area holds the expectation is for a retest and break of recent highs $10.00 area.
2. IDT (IDT)
IDT is a pharmaceutical company based in Melbourne and a solid contender to manufacture a COVID-19 mRNA vaccine for the Australian government. The share price of IDT initially rallied from .17c in March of this year when IDT issued a release, noting it was assessing the viability of producing a vaccine. In late August, it announced it was in a “state of readiness to produce a COVID-19 vaccine” that propelled the shares up to .755c. IDT is one of the only pharmaceutical companies in Australia with a sterile facility ready to produce a vaccine and probably the only one with spare capacity. For this reason and given the need for vaccines to be produced locally in the years to come, IDT is a company worth a second look.
3. QANTAS (QAN)
Australia’s national airline is currently enjoying the prospect of reopening as domestic vaccination rates continue to climb. Tourism Minister Dan Tehan said today that Australians will be able to travel aboard unrestricted by no later than Christmas once the vaccination rate in their respective states hits 80%. The Qantas stock price has rallied over 30% in the past three weeks from $4.20 to a high of $5.56, in anticipation of a travel boom from pent-up demand from a nation of people who love to travel. Dips should be well supported near $5.00 looking for a test of the November 2020, $5.79 high, before the next upside target at $6.20.
Source Tradingview. The figures stated areas of September 22nd, 2021. Past performance is not a reliable indicator of future performance. This report does not contain and is not to be taken as containing any financial product advice or financial product recommendation
Latest market news
View more newsThe complete CFD trading experience
Award-winning platforms, competitive spreads, low commissions and dedicated support.
We live and breathe the markets and are dedicated to helping traders realise their ambitions as we continue to set the industry bar.
Economic calendar
Web Trader platform
Our sophisticated web-based platform is packed with features.

S&P 500, Nasdaq, Dow Forecast: Rising Yields Test Rally Ahead of Nvidia, Fed 8 22 2026
S&P 500, Nasdaq and Dow test key technical levels as momentum fades, raising the risk of a deeper correction heading into a pivotal week.

ASX 200 Futures Reversal Patterns Put to the Test
Not all reversal patterns are created equal. Historical ASX 200 futures data shows which signals have been more reliable, and why risk management still matters.

Cyclical stocks sniff out better times ahead
Different economies, different drivers, similar price action. The German DAX, ASX 200 and Russell 2000 are all hinting at a more optimistic view on the global economy.
StoneX Europe Ltd may make third party material available on this website which may contain information included but not limited to the conditions of financial markets. The material is for information purposes only and does not contain, and should not be construed as containing, investment advice and/or investment recommendation and/or an investment research and/or an offer of or solicitation for any transactions in financial instruments; any decision to enter into a specific transaction shall be made by the client following an assessment by him/her of their situation.
StoneX Europe Ltd makes no representation or warranty and assumes no liability as to the accuracy or completeness of the information provided, nor any loss arising from any investment based on a recommendation, forecast or other information supplied. You should always seek independent advice as to your suitability to speculate in any related markets and your ability to assume the associated risks, if you are at all unsure. We are not under any obligation to update any such material. Any opinion made may be personal to the author and may not reflect the opinion of StoneX Europe Ltd.






